MARKET

CLDI

CLDI

Calidi Biotherapeutics Inc
AMEX
0.7018
+0.0418
+6.33%
Pre Market: 0.7467 +0.0449 +6.40% 06:32 10/29 EDT
OPEN
0.6995
PREV CLOSE
0.6600
HIGH
0.7189
LOW
0.6640
VOLUME
432
TURNOVER
0
52 WEEK HIGH
27.04
52 WEEK LOW
0.6200
MARKET CAP
2.58M
P/E (TTM)
-0.0071
1D
5D
1M
3M
1Y
5Y
1D
Calidi Biotherapeutics Reports Two Posters At European Society For Medical Oncology From Its RedTail Platform
Benzinga · 2d ago
Weekly Report: what happened at CLDI last week (1019-1023)?
Weekly Report · 3d ago
Calidi Biotherapeutics To Present Preclinical Data On CLD-401 And In Situ T-Cell Engager Programs At ESMO 2026, Highlighting Tumor Eradication And Antitumor Activity Findings
Benzinga · 10/19 12:06
Weekly Report: what happened at CLDI last week (1012-1016)?
Weekly Report · 10/19 09:46
Weekly Report: what happened at CLDI last week (1005-1009)?
Weekly Report · 10/12 09:49
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/06 21:05
Weekly Report: what happened at CLDI last week (0928-1002)?
Weekly Report · 10/05 09:49
Weekly Report: what happened at CLDI last week (0921-0925)?
Weekly Report · 09/28 09:46
More
About CLDI
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.

Webull offers Calidi Biotherapeutics Inc stock information, including AMEX: CLDI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLDI stock methods without spending real money on the virtual paper trading platform.